Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6060866 | 1.00 | NPSR1 (0.31) | NPSR1GLO1 | |
| SCHEMBL6060862 | 1.00 | NPSR1 (0.31) | NPSR1GLO1 | |
| SCHEMBL10433472 | 0.86 | — | — | |
| SCHEMBL10433457 | 0.86 | — | — | |
| SCHEMBL21319868 | 0.85 | NPSR1 (0.33) | NPSR1GLO1 | |
| SCHEMBL1443700 | 0.84 | CYP2D6 (0.41) | NPSR1GLO1 | |
| SCHEMBL1443696 | 0.84 | CYP2D6 (0.41) | NPSR1GLO1 | |
| SCHEMBL9500786 | 0.81 | GABRR1 (0.37) | — | |
| SCHEMBL9500796 | 0.81 | GABRR1 (0.37) | — | |
| SCHEMBL9500792 | 0.81 | GABRR1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012098-B2 | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers | PHARMACIA CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1463495-A4 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6951889-B2 | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | PHARMACIA CORPORATION | 2005-09-15 | — | — | US | disclosed |
| US-20050113451-A1 | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1528921-A2 | METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL CONDITIONS | Pharmacia Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| EP-1317421-B1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORP (US) | 2005-02-23 | — | — | EP | disclosed |
| EP-1505972-A2 | A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1506040-A2 | SELECTIVE INOS INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES AND CONDITIONS | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1463495-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040087653-A1 | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor | MANNING PAMELA T (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | MANNING PAMELA T (US) | 2004-04-22 | — | — | US | disclosed |
| WO-2004012726-A2 | METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL CONDITIONS | PHARMACIA CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003097163-A2 | USING A SELECTIVE INOS INHIBITOR FOR THE TREATMENT OF RESPIRATORY DISEASES AND CONDITIONS | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097050-A2 | A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030119826-A1 | Neuroprotective treatment methods using selective iNOS inhibitors | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030109522-A1 | Ophthalmologic treatment methods using selective iNOS inhibitors | PHARMACIA CORPORATION | 2003-06-12 | — | — | US | disclosed |
| US-20030013702-A1 | Agents and methods for treatment of cancer | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | disclosed |
| WO-2002076395-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020132849-A1 | 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013702-A1 | Agents and methods for treatment of cancer | FAP, APC, PTGIS | NPSR1 3383/4885GLO1 201/4885 |
| US-20040087653-A1 | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor | NOS2, NOS1, PDE3A | NPSR1 1729/4885GLO1 349/4885 |
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | NOS2, NOS1, NOS3 | NPSR1 1284/4885GLO1 324/4885 |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | NOS2, NOS1, NOS3 | NPSR1 3888/4885GLO1 812/4885 |
| US-20020132849-A1 | 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PTGIS, ALOX5, ALOX15 | NPSR1 1080/4885GLO1 673/4885 |
| US-20050113451-A1 | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PTGIS, ALOX5, ALOX15 | NPSR1 1080/4885GLO1 673/4885 |
| US-20030109522-A1 | Ophthalmologic treatment methods using selective iNOS inhibitors | NOS2, NOS1, NOS3 | NPSR1 1472/4885GLO1 125/4885 |
| US-20030119826-A1 | Neuroprotective treatment methods using selective iNOS inhibitors | NOS2, NOS1, NLN | NPSR1 677/4885GLO1 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.